Notwithstanding encouraging clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable opposition from pharmacy benefit managers. These organizations are typically creating obstacles to coverage, including high expense restrictions and PA that restrict user availab… Read More